Small molecule inhibitors of the acetyl-histone binding protein BRD4 have been shown to block cardiac fibrosis in pre-clinical models of heart failure (HF). However, the mechanisms by which BRD4 promotes pathological myocardial fibrosis remain unclear. Here, we demonstrate that BRD4 functions as an effector of TGF-β signaling to stimulate conversion of quiescent cardiac fibroblasts into Periostin (Postn)-positive cells that express high levels of extracellular matrix.
Background
Fibrosis is a stereotypical wound-healing response that is mounted after tissue injury or stress.
A significant body of clinical data has demonstrated that myocardial fibrosis is strongly associated with adverse outcomes in several forms of human heart failure (HF), including HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and genetically driven cardiomyopathies 1, 2 . While fibrotic responses may acutely serve to stabilize a focal area of myocardial damage, clinical and experimental studies support the contention that excessive, diffuse, or chronic activation of the fibrotic process can be deleterious to long-term cardiac function and patient survival. For example, interstitial fibrosis increases the passive stiffness of the myocardium, contributing to diastolic dysfunction 3, 4 , and disrupts electrical conduction in the heart, causing arrhythmias and sudden cardiac death 5 . Unfortunately, despite the well-accepted roles of fibrosis in cardiac dysfunction, no targeted anti-fibrotic drugs for the heart exist.
As such, understanding the fundamental mechanisms driving cardiac fibrosis and discovering novel approaches to target this process are of significant scientific and therapeutic interest.
The adult heart contains a large number of resident cardiac fibroblasts, which are developmentally derived from the epicardium and play important roles in maintaining tissue architecture [6] [7] [8] . In response to injury, resident tissue fibroblasts undergo a dramatic cell state transition to become activated fibroblasts 9 , sometimes referred to as myofibroblasts, which are characterized by expression of the marker gene Periostin (Postn) 10, 11 . This transition is associated with rewiring of the transcriptome to endow the activated fibroblasts with the capability to proliferate, migrate, secrete pro-inflammatory mediators and secrete fibrotic extracellular matrix (ECM). A causal role for activated fibroblasts in cardiac fibrosis was established employing mice in which a tamoxifen-inducible Cre cassette was used to selectively deplete Postn-positive fibroblasts using diphtheria toxin 11 . In these mice, deletion of Postn-positive fibroblasts blunted cardiac fibrosis in response to angiotensin II infusion or myocardial infarction 11 .
Cardiac fibroblast activation is driven, in part, by transforming growth factor-β (TGF-β), which signals through a heterodimeric cell surface receptor complex consisting of TGFβ receptor type I (TGFβRI) and II (TGFβRII) 12, 13 . Canonical TGF-β signaling leads to phosphorylation and nuclear import of SMAD transcription factors, which bind to regulatory elements in a variety of pro-fibrotic genes. Deletion of TGF-β receptors or the SMAD3 family member in Postn-positive fibroblasts suppresses cardiac fibrosis in response to pressure overload in mice 14 . TGF-β can also promote fibrosis by stimulating SMAD-independent, noncanonical pathways, such as those governed by mitogen-activated protein kinases (MAP kinases). For example, cardiac fibroblasts lacking p38α are resistant to pro-fibrotic TGF-β signaling, and deletion of p38α in Postn-positive fibroblasts in vivo blunts cardiac fibrosis in response to myocardial infarction 15, 16 . Transcriptional effectors of non-canonical TGF-β signaling in fibroblasts include nuclear factor of activated T cells (NFAT), serum response factor (SRF) and myocardin-related transcriptional cofactors (MRTFs) [17] [18] [19] [20] [21] .
Recently, a family of epigenetic reader molecules called bromodomain and extraterminal (BET) acetyl-lysine binding proteins was shown to control pathological fibrosis 22 . JQ1, a first-inclass, potent and specific inhibitor of BET bromodomains that functions by competitively displacing BET proteins from acetylated-histones 23 , was found to block cardiac fibrosis in mice subjected to pressure overload or myocardial infarction [24] [25] [26] . Bulk RNA-seq analysis of left ventricular tissue homogenates demonstrated the ability of JQ1 to block expression of fibroblasts activation markers, including Postn 25 . However, the mechanism by which BET protein inhibition suppressed fibrotic remodeling in the heart remained undefined. Here, we
show that JQ1 potently inhibits cardiac fibroblast activation, and that the BET family member, BRD4, functions as a downstream effector that couples pro-fibrotic TGF-β signaling to the epigenome in cardiac fibroblasts. The findings reveal a critical role for a chromatin reader protein in the epigenetic control of pathological cardiac fibrosis and HF.
Results

BRD4 inhibition blocks TGF-β-mediated cardiac fibroblast activation
When placed in a collagen gel, activated fibroblasts exhibit the ability to contract due to expression of α-smooth muscle actin (α-SMA) 27, 28 , and this process can be enhanced by stimulation with TGF-β 29 . To begin to address the potential role of BRD4 in the control of cardiac fibroblast activation, primary adult rat ventricular fibroblast (ARVF) cultures were incorporated into collagen gels and stimulated with TGF-β in the absence or presence of JQ1.
JQ1 significantly reduced basal and TGF-β-mediated collagen gel contraction in association with a profound reduction in α-SMA protein expression ( Fig. 1a-c ). Using specific siRNAs, knockdown of BRD4, but not BRD2 or BRD3, suppressed TGF-β-mediated induction of α-SMA ( Fig. 1d,e ). These data suggest that BRD4 is the primary BET family member that regulates cardiac fibroblast activation.
BRD4 inhibition blocks TGF-β-mediated mRNA and protein expression in cardiac fibroblasts
To further address the role of BRD4 in cardiac fibroblast activation, transcriptomic profiling by RNA sequencing (RNA-seq) was performed using RNA from ARVFs stimulated with TGF-β for 24 hours in the absence or presence of JQ1. Using a >two-fold expression change, minimum average expression of 5 FPKM, and a false discovery rate (FDR) of <0.05 as cutoffs, differential expression analysis showed that TGF-β increased expression of 174 genes and reduced expression of 236 genes which are depicted in heat map format ( Fig. 2a ). Data from cells treated with TGF-β in the presence of JQ1 are also included in the heat map. Ingenuity Pathway Analysis (IPA) of TGF-β-induced transcripts showed a strong enrichment for fibrosis and inflammatory signaling ( Fig. 2b) ; the top 5 enriched pathways in TGF-β treated ARVFs in the absence or presence of JQ1 are shown. IPA also revealed that JQ1 profoundly suppressed expression of target genes that are known to be directly downstream of TGF-β signaling ( Fig.   2c,d) .
Postn was among the most strongly downregulated transcripts in JQ1 treated ARVFs, further supporting a role for BRD4 in the control of cardiac fibroblast activation ( Fig. 2c,d , black arrows). Quantitative mass spectrometry confirmed that the BET inhibitor blocked TGF-βinduced expression of Periostin protein (Supplemental Fig.1a ). Furthermore, principal component analysis of relative protein abundance in whole-cell ARVF homogenates indicated clear segregations in the constellation of proteins expressed in unstimulated ARVFs compared to those in cells treated with TGF-β in the absence or presence of JQ1 (Supplemental Fig. 1b ).
Differential expression analysis revealed that TGF-β treatment significantly induced the expression of 64 proteins (adjusted P-value < 0.05). As depicted in the heat map, JQ1 blocked induction of a subset, but not all, TGF-β-induced proteins (Supplemental Fig. 1c ; Periostin is indicated with a black arrow).
BRD4 inhibition blocks TAC-induced changes in cardiac fibroblast gene expression in vivo
To determine whether BRD4 inhibition also suppresses cardiac fibroblast activation in the heart in vivo, mice were subjected to transverse aortic constriction (TAC) and treated with JQ1 or vehicle control by intraperitoneal injection every other day for two weeks ( Fig. 3a) . At the completion of the study, cardiac fibroblasts were isolated from the hearts of the mice as well as sham controls, and transcriptomic profiling of these cells was performed by RNA-seq; RNA was prepared from the cells immediately following isolation. Using a >two-fold expression change and a FDR <0.05 as cutoffs, 64 transcripts were found to be significantly upregulated in cardiac fibroblasts following TAC and significantly inhibited by JQ1 ( Fig. 3b ). Consistent with the cell culture data, TAC-induced Postn mRNA expression was dramatically repressed in fibroblasts from JQ1-treated mice (Fig. 3b, arrow) . Additionally, IPA analysis revealed a strong enrichment for fibrosis and inflammatory signaling in cardiac fibroblasts post-TAC ( Fig. 3c) ; the top 5 enriched pathways in cardiac fibroblasts from mice subjected to pressure overload in the absence or presence of JQ1 are shown. The impact of TAC and JQ1 on expression of fibrosisand inflammation-associated mRNA transcripts is depicted ( Fig. 3d ). Together, the findings suggest that BRD4 regulates cardiac fibroblast activation in response to pressure overload in vivo.
BRD4 binding to cardiac fibroblast enhancers is dynamically regulated by TGF-β
To address the mechanism by which BRD4 promotes cardiac fibroblast activation, ARVFs were subjected to whole-genome chromatin immunoprecipitation-sequencing (ChIP-seq) to map gene regulatory elements bound by BRD4. ARVFs were treated with vehicle control or stimulated with TGF-β for 24 hours prior to preparation of sheared chromatin ( Fig. 4a ). ChIP was performed separately with BRD4-and RNA Pol II-specific antibodies, and associated cardiac fibroblast DNA was subject to deep sequencing. Aggregate analysis of the two groups revealed well-defined peaks of BRD4 binding to 7,813 gene enhancers, with enhancers defined as being at least 2,500 base pairs (bp) from the transcription start site (TSS) of the associated gene ( Fig.   4b ). Prominent BRD4 binding was also detected at 4,069 gene promoters, defined as TSSs +/-1000 bp (Supplemental Figure 2 ).
To assess whether genomic targeting of BRD4 in cardiac fibroblasts is under signaldependent control, we evaluated binding of the protein to 4,674 genes (enhancers and promoters combined), which are defined as active genes based on the presence of RNA Pol II in the TSS +/-1000 bp region, and an fpkm >= 10. Three general patterns of BRD4 dynamics were observed: (i) increased BRD4 binding upon TGF-β stimulation, (ii) loss of BRD4 binding following TGF-β stimulation, and (iii) constitutive BRD4 binding that is unchanged by TGF-β treatment ( Fig. 4c, top panel) ; the 400 genes where BRD4 association with regulatory elements was most dramatically increased and decreased are highlighted in red and green, respectively.
BRD4 abundance correlated with downstream target gene expression ( Fig. 4c , bottom panel).
Comparison of BRD4 and RNA Pol II ChIP-seq signals suggested that association of BRD4 with regulatory elements for the 4,674 genes is coupled to productive transcription elongation, since RNA Pol II abundance within the bodies of the genes correlated with the degree of BRD4 binding ( RNA Pol II dynamics were further scrutinized by focusing on the top 400 genes where BRD4 binding was most dramatically increased or decreased in response to TGF-β. ChIP-seq showed that TGF-β stimulation enhanced gene-body enrichment of RNA Pol II when BRD4 was gained at enhancers/promoters, but decreased gene-body enrichment of RNA Pol II when the presence of BRD4 was reduced at regulatory sites upon cellular stimulation ( Fig. 4e ,f). These findings corroborate a critical role for BRD4 in TGF-β-coupled pause release of RNA poll II at upregulated genes in cardiac fibroblasts.
TGF-β-mediated recruitment of BRD4 to Sertad4 enhancers and super-enhancers
To further interrogate signal-dependent regulation of BRD4 genomic localization in cardiac fibroblasts, subsequent analyses focused on enhancers and super-enhancers (SEs), which are long-range gene regulatory elements that have been defined in cancer and immune cells based on abundant BRD4 binding above a threshold level found at typical enhancers [30] [31] [32] . Dynamic, signal-regulated targeting of BRD4 in cardiac fibroblasts is exemplified by the Sertad4 locus, where the chromatin reader was readily detected in association with the promoter region and six distinct proximal enhancers (E1 -E6) ( Fig. 5a , top panel). TGF-β treatment led to enhanced binding of BRD4 to each of these sites, with profound enrichment occurring at E1 and E2 (Fig.   5a , bottom panel). Based on the level of BRD4 association, both E1 and E2 were categorized as SEs following stimulation with the pro-fibrotic agonist. In total, 147 and 116 BRD4-enriched SEs were detected in unstimulated and TGF-β stimulated cardiac fibroblasts, respectively ( Fig.   5b ). The ranking of E1 and E2, commensurate with BRD4 abundance before and after TGF-β stimulation, is indicated (Fib. 5b, yellow and green circles). Consistent with a regulatory role for BRD4, TGF-β-induced expression of Sertad4 was blocked by JQ1 ( Fig. 5c ).
p38 MAP kinase regulates TGF-β-mediated recruitment of BRD4 to Sertad4 enhancers and super-enhancers
The Sertad4 locus was employed as a prototype to begin to define the signaling pathways that couple TGF-β receptor activation to chromatin targeting of BRD4 in cardiac fibroblasts. Initially, a panel of pharmacological inhibitors was employed to address whether known effectors of cardiac fibroblast activation regulate agonist-dependent expression of Sertad4 (Fig. 6a ). As shown in Figure 6b , inhibition of p38 mitogen-activated protein kinase, but not extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) or the calcineurin phosphatase, suppressed TGF-β-induced Sertad4 mRNA expression in ARVFs. Subsequently, ChIP-PCR was used to address the hypothesis that p38 kinase activity contributes to signal-dependent chromatin targeting of BRD4 ( Fig. 6c ). Consistent with the mRNA expression data, pan-p38 inhibition with SB203580 led to significant decreases in binding of BRD4 to the promoter region 1 0
of the Sertad4 gene, as well as each of the six enhancers/super-enhancers defined Figure 5 .
These data suggest that p38 signaling is involved in controlling BRD4 loading on gene regulatory elements in cardiac fibroblasts.
Sertad4 regulates TGF-β-mediated induction of markers of cardiac fibroblast activation
Sertad4 has not previously been implicated in the regulation of cardiac fibroblast activation.
Thus, to address the functional relevance of BRD4-mediated control of this factor, RNA interference was used to knock down expression of Sertad4 in ARVFs. Two independent lentivirus-encoded shRNAs efficiently repressed basal and TGF-β-induced expression of Sertad4 ( Fig. 7a ). Furthermore, Sertad4 knockdown markedly reduced TGF-β stimulated expression of α-SMA and Postn in the cardiac fibroblasts ( Fig. 7b,c ), suggesting that SERTAD4 protein contributes to cardiac fibroblast activation.
Discussion
Epigenetic mechanisms that regulate cardiac fibrosis remain poorly understood. Here, we demonstrate that the BRD4 chromatin reader protein is crucially involved in promoting cardiac fibroblast activation. BRD4 binding to discrete gene enhancers in fibroblasts can be altered by TGF-β receptor signaling in a p38 kinase-dependent manner, providing a circuit for coupling extracellular cues to the cardiac epigenome to drive pro-fibrotic gene expression ( Fig. 7d ).
Our prior RNA-seq analyses demonstrated the ability of JQ1 to block expression of canonical markers of fibroblast activation in the LV in mouse TAC and MI models 25 . However, interpretation of these data was complicated by the use of bulk RNA from whole LV tissue
homogenates. In the current study, we demonstrate that JQ1 profoundly inhibits expression of activation markers and ECM proteins in cultured cardiac fibroblasts treated with TGF-β, and in cardiac fibroblasts isolated from LVs of animals subjected to TAC. JQ1 also suppressed the contractile activity of cardiac fibroblasts in association with repression of expression of α-SMA.
These data suggest that BRD4 functions in a fibroblast-autonomous manner to promote fibrotic remodeling of the heart.
We performed parallel ChIP-seq and RNA-seq to address, mechanistically, how BRD4 regulates fibroblast activation. Remarkably, to our knowledge, the resulting data represent the first genome-wide evaluation of epigenetic regulatory events in cardiac fibroblasts. The findings revealed that BRD4 is positioned at thousands of discrete enhancers and promoters throughout the cardiac fibroblast genome. In response to TGF-β treatment, the amount of BRD4 increases at a subset of these sites, while in other cases it decreases or is unaffected by the pro-fibrotic signal. This signal-dependent regulation of BRD4 is analogous to what we previously observed in cardiomyocytes treated with a hypertrophic agonist 33 , although the genomic localization of BRD4 in fibroblasts versus myocytes is clearly distinct. In the current study, assessment of genes proximal to the BRD4 peaks demonstrated a correlation between BRD4 abundance at enhancers/promoters, RNA Pol II level within the gene body, and mRNA expression in cardiac fibroblasts. This relationship is consistent with the ability of BRD4 to stimulate gene expression by promoting transcriptional elongation and release of paused RNA Pol II [34] [35] [36] . It is interesting to note that the number of BRD4-enriched enhancers in unstimulated cardiac fibroblasts actually decreased following TGF-β stimulation, suggesting that BRD4 activity needs to be repressed at certain genes in order for fibroblasts to become activated and secrete ECM. In other cellular contexts, coordinately deployed transcription factors recruit BRD4 to active cis-regulatory elements in a manner that is dependent on the underlying acetyl-histone landscape of chromatin 37 . We posit that signal-dependent alterations in transcription factor occupancy and histone acetyltransferase/deacetylase activity govern genome-wide redistribution of BRD4 to drive cardiac fibroblast activation.
ChIP-PCR analysis demonstrated that treatment of cardiac fibroblasts with the p38 inhibitor, SB203580, blunted TGF-β-mediated recruitment of BRD4 to enhancers proximal to the gene encoding Sertad4, resulting in reduced Sertad4 mRNA expression. p38 kinase has long been recognized as an effector of pathological cardiac remodeling 38 , and a recent report demonstrated that p38α within cardiac fibroblasts mediates pro-fibrotic TGF-β signaling in the heart 15, 16 . Deletion of p38α (Mapk14 gene) in cultured fibroblasts blocked differentiation of the cells into α-SMA-positive fibroblasts in response to TGF-β, angiotensin II (Ang II) or cyclic stretching. This block could be overcome by ectopic overexpression of the canonical transient receptor potential 6 (TRPC6) channel, a constitutively active form of the calcineurin phosphatase, or the serum response factor (SRF) transcription factor, suggesting that p38α lies upstream of these proteins, all of which have been demonstrated to regulate myofibroblast differentiation 17 . Our data define BRD4 as another downstream effector of pro-fibrotic p38 signaling. The mechanism by which p38 controls BRD4, and the extent to which this kinase regulates the genome-wide distribution of BRD4 in cardiac fibroblasts and other cell types, remain to be determined.
SERTAD4 is a member of the SERTAD family of proteins 39, 40 , which are also known as
Trip-Br or SEI proteins 41 . SERTAD proteins are characterized by the presence of a conserved SERTAD (SEI, RBT1, TARA) domain 39, 41, 42 . Members of this family have been shown to regulate cell cycle progression by virtue of their ability to interact with CDK/cyclin complexes 43 , and also by functioning as transcriptional co-factors to positively or negatively control E2Fdependent transcription 42 . The biological function of SERTAD4, which is nuclear protein that appears to lack intrinsic transcriptional activity 44 , is largely unknown. However, the related protein, SERTAD1, was found to act as a transcriptional co-activator of SMAD1 to stimulate BMP target gene expression 45 . We demonstrate that TGF-β stimulates Sertad4 expression, and that knockdown of this factor blunts TGF-β-induced expression of activation markers in cardiac fibroblasts. It is intriguing to speculate that, analogous to the BMP/SERTAD1 axis, The BET family consists of BRD2, BRD3, BRD4 and BRDT, all of which contain tandem bromodomains. JQ1, which is a specific pan-inhibitor of all BET family members, has shape complementarity to the acetyl-lysine binding pocket within the bromodomains of these proteins 23 . JQ1 competitively and reversibly displaces BETs from acetyl-histones on active enhancers, thereby disrupting downstream signaling events to RNA Pol II. We previously demonstrated that JQ1 treatment reduces interstitial fibrosis in mouse TAC and MI models [24] [25] [26] . Recently, the ability of JQ1 to block cardiac fibrosis in the TAC model was confirmed by an independent group, and was associated with reduced endothelial to mesenchymal transition 46 . JQ1 has also been shown to blunt fibrosis in other organ systems, including lung [47] [48] [49] , kidney 50 , liver and pancreas 51, 52 . Collectively, the data underscore the therapeutic potential of BET inhibitors for the treatment of diverse fibrotic diseases. Nonetheless, there is reasonable concern about potential toxicities of pan-BET inhibitors 53 , which is highlighted by to adverse effects such as thrombocytopenia and nausea observed in clinical trials evaluating bromodomain inhibitors in cancer clinical trials 54 .
BRD4 is a key pro-fibrotic BET family member. The data presented here enhance our understanding of the molecular mechanisms by which BRD4 controls pathogenic gene expression in fibroblasts. Together with forthcoming findings, this knowledge should yield a cumulative framework that guides the development of more selective BRD4 inhibitors, as opposed to pan-BET inhibitors, with the potential to provide a therapeutic window that is suitable for the treatment of chronic fibrotic diseases such as HF.
Methods
Cardiac fibroblast isolation and culture. Adult rat ventricular fibroblasts (ARVFs) were isolated from female Sprague Dawley rats using enzymatic digestion (1 mg/ml collagenase type II; Worthington Biochemical Corporation) followed by gentle centrifugation for collection of cells, as previously described 55 . Cells were maintained in DMEM/F12 media supplemented with 20% FBS, 1 % antibiotics-L glutamine and 1 μmol/L ascorbic acid. ARVFs were then passaged once to P1 (passage 1) or twice to P2 (passage 2), and plated appropriately for downstream assays.
Equilibration of cells in low serum medium (0.1% FBS) was carried out prior to all treatments. Table S1 .
RNA-seq analysis using freshly isolated mouse cardiac fibroblasts. Total RNA was prepared from fibroblasts isolated from mouse hearts using Direct-zol RNA miniprep kit (Zymo Research). cDNA libraries were prepared using the NEBNext Ultra Directional Library Preparation Kit following rRNA depletion using the NEB rRNA depletion kit. Libraries were submitted to the UC Denver Genomics and Microarray core facility for sequencing (HiSeq2000).
Reads were trimmed with Trim Galore! (v.0.3.7) and aligned with STAR (v.2.5.2a) 63 to the mouse genome (Mm10) with annotations from UCSC (July 2016). Raw counts were loaded in to R 64 . Genes with a median of <1 mapped read per million were removed before differential expression analysis with edgeR 65 . Raw and processed RNA-seq data were deposited to the GEO online database (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSExxxxx.
ChIP-seq and ChIP-PCR. Anti-BRD4 (301-985, Bethyl Laboratories) and anti-RNA Pol II (39097, Active Motif) Chromatin Immunoprecipitation was performed as previously described 33 .
Five independent 10-cm plates of ARVFs were combined per immunoprecipitation. Libraries were prepared using the Rubicon TruPLEX Tag-seq kit and submitted to the UC Denver Genomics and Microarray core facility for sequencing (HiSeq2000). For validation of BRD4bound enhancers or super-enhancers of the Sertad4 locus, ChIP was performed as described above. The immunoprecipitates were collected and eluted DNA was subjected to qPCR using specific primers (Integrated DNA Technologies; primer sequences are listed in Table S2 . ChIP-seq analysis. All ChIP-seq datasets were aligned using Bowtie2 (version 2.2.1) to build version RN4 of the rat genome 67 . Alignments were performed using the following criteria: -k 1.
RNA-seq and analysis using
These criteria preserved only reads that mapped uniquely to the genome. ChIP-seq read densities were calculated and normalized using Bamliquidator 0 (https://github.com/bradnerlab/pipeline/) was used to identify BRD4 enhancers and superenhancers, as previously described 30 . Briefly, proximal regions of BRD4 enrichment were stitched together if within 2 kb of one another. This 2 kb stitching parameter was determined by ROSE2 as the distance that optimally consolidated the number of discreet enriched regions in the genome while maintaining the largest fraction of enriched bases per region. Comparison of BRD4 changes at enhancers, super-enhancers, and promoter regions was performed as previously described 30 . Active genes, defined by presence of RNA Pol II in the TSS +/-1 kb region, within 50 kb of enhancer regions were assigned as target genes, as described previously 30 . Promoters for heat maps were identified by overlapping TSS -/+ 1,000 bp regions with peaks from treated and unstimulated BRD4 ChiP-seq data. Enhancer and promoter heat Fig. 2c , the mechanistic network for TGF-β in the analysis was displayed. Then target genes (table provided below the network in IPA) were added to the network. Next, network hubs were deleted (hence some molecules without direct lines from TGF-β). Finally, reduced genes were deleted and induced genes were manually placed to allow visualization. Representation of the same genes to reflect changes from the insult to insult +JQ1 analysis ( Fig. 2d and Fig. 3d ) was accomplished using the "build" and 
